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Unique members of the nucleotide-binding domain leucine-rich repeat (NLR) family have
been found to regulate intracellular signaling pathways initiated by other families of
pattern recognition receptors (PRR) such as Toll-like receptors (TLRs) and retinoic-acid
inducible gene I (RIG-I)-like receptors (RLRs). Plasmacytoid dendritic cells (pDCs),
the most powerful type I interferon (IFN) producing cells, preferentially employ
endosomal TLRs to elicit antiviral IFN responses. By contrast, conventional DCs (cDCs)
predominantly use cytosolic RLRs, which are constitutively expressed in them, to sense
foreign nucleic acids. Previously we have reported that, though RIG-I is absent from
resting pDCs, it is inducible upon TLR stimulation. In the recent study we investigated
the regulatory ability of NLRs, namely NLRC5 and NLRX1 directly associated with the
RLR-mediated signaling pathway in DC subtypes showing different RLR expression,
particularly in pDCs, and monocyte-derived DCs (moDCs). Here we demonstrate that
similarly to RLRs, NLRC5 is also inducible upon TLR9 stimulation, whereas NLRX1
is constitutively expressed in pDCs. Inhibition of NLRC5 and NLRX1 expression in
pDCs augmented the RLR-stimulated expression of type I IFNs but did not affect the
production of the pro-inflammatory cytokines TNF, IL-6, and the chemokine IL-8. Further
we show that immature moDCs constantly express RLRs, NLRX1 and NLRC5 that are
gradually upregulated during their differentiation. Similarly to pDCs, NLRX1 suppression
increased the RLR-induced production of type I IFNs in moDCs. Interestingly, RLR
stimulation of NLRX1-silenced moDCs leads to a significant increase in pro-inflammatory
cytokine production and IκBα degradation, suggesting increased NF-κB activity. On
the contrary, NLRC5 does not seem to have any effect on the RLR-mediated cytokine
responses in moDCs. In summary, our results indicate that NLRX1 negatively regulates
the RLR-mediated type I IFN production both in pDCs and moDCs. Further we show
that NLRX1 inhibits pro-inflammatory cytokine secretion in moDCs but not in pDCs
following RLR stimulation. Interestingly, NLRC5 suppresses the RLR-induced type I
IFN secretion in pDCs but does not appear to have any regulatory function on the
RLR pathway in moDCs. Collectively, our work demonstrates that RLR-mediated innate
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immune responses are primarily regulated by NLRX1 and partly controlled by NLRC5 in
human DCs.
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INTRODUCTION
DCs, acting as sentinels of the immune system, recognize
various molecular motifs within pathogens through their
PRRs and rapidly produce inflammatory cytokines and/or
antiviral molecules to initiate innate immune responses (1).
In order to fulfill this task, DCs are equipped with an
arsenal of germ-line encoded PRRs including TLRs, RLRs and
NLRs (2). Recent evidence indicates that these PRRs might
collaborate synergistically to counteract the infectious agents or
antagonistically to attenuate overzealous inflammation (3–5). In
this report our primary goal was to reveal possible interactions
between RLRs and NLRs in different human DC subtypes.
RLRs function as cytoplasmic sensors of viral RNA and
trigger type I IFN production and antiviral gene expression
to control viral infection (6–8). To date, three RLR members
have been identified: RIG-I, Melanoma differentiation-associated
gene-5 (MDA5), and their regulatory molecule, Laboratory of
genetics and physiology 2 (LGP2), which are broadly expressed
in most tissues (6, 9). RIG-I, the prototypical member of the RLR
family, preferentially recognizes short RNA sequences marked
with 5′ triphosphorylated (5′ppp) ends (10). In contrast to RIG-I,
MDA5 predominantly recognizes long dsRNAs (11). Although
many natural ligands including incoming viral nucleocapsids
(12), virus genomes (13), virus replication intermediates (14), or
viral transcripts (15, 16) are recognized by RIG-I (10), genomic
RNA generated by viral replication seems to constitute the
major trigger (17). These findings suggest that RIG-I stimulation
requires the presence of actively replicating viruses, in contrast
to endosomal TLRs, which are mainly activated by internalized
viruses, phagocytosed infected materials or apoptotic cell debris
(18, 19).
Upon activation, RLRs translocate to mitochondria where
they interact with the mitochondrial antiviral signaling adaptor
(MAVS). RLR-MAVS interaction leads to the recruitment of
downstream signaling factors, such as inhibitor of kappa kinases
(IKK) and Tank-binding kinase 1 (TBK1) which activate nuclear
factor-κB (NF-κB) and interferon regulatory factor (IRF) 3 that
are crucial for the induction of type I IFNs, inflammatory
cytokines and chemokines, respectively (6, 10). RIG-I and
MDA5 have been found to be differently expressed by distinct
DC subtypes; they are constitutively expressed in cDCs and
macrophages, whereas absent or maintained at low levels in
resting pDCs (20–22). It has been suggested that pDCs mainly
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mitochondrial antiviral-signaling protein; MDA5, Melanoma differentiation-
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polyinosinic:polycytidylic acid; PRR, pattern recognition receptor; RIG-I, retinoic-
acid inducible gene I; RLR, RIG-I-like receptors; TLR, Toll-like receptors; VSV,
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rely on endosomal TLRs for recognition of viruses whereas other
cells such as cDCs preferentially use cytosolic RLRs to recognize
replicating viral RNA intermediates (23, 24). Intriguingly it has
been found that in the absence of IFN positive feedback mouse
pDCs can mount an antiviral response through a synergistic
TLR- and RLR-dependent recognition and type I IFN production
(25). In line with this, we recently reported that pDCs express
RIG-I at very low level under steady-state conditions; however
its expression can be greatly upregulated by endosomal TLR
stimulation in a type I IFN-independent manner (26). We have
also proposed a model where endosomal TLRs mediate the early
phase of type I IFN production in pDCs while RIG-I participates
in the late phase of IFN responses (27).
NLRs constitute a large family of intracellular PRRs,
that can be divided into four functional categories: signal
transduction, inflammasome assembly, transcriptional activation
and autophagy (28). Recently certainmembers of the NLR family,
known as regulatory NLRs, have been found to modulate diverse
signaling pathways including the NF-κB, mitogen-activated
protein kinase (MAPK) and type I IFN responses (4, 29). The role
of regulatory NLRs is widely studied in animal models, but little is
known about their regulatory functions in human cells, especially
in DCs, which are essential for both innate and adaptive antiviral
responses. However, to maintain immune balance NF-κB and
type I IFN signaling must be tightly regulated in these cells (30).
So far two regulatory NLRs, namely NLRC5 and NRLX1, have
been assigned to the RIG-I-mediated signaling pathway, though
conflicting results have been reported with regard to their role in
the regulation of antiviral innate immune responses (31).
In this study our goal was to explore the expression profile
of these regulatory NLRs and to reveal their contribution to the
RLR-mediated cytokine responses using a human pDC cell line
and human moDCs.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
The human pDC cell line (GEN2.2) was used in our experiments
which was generated by Joël Plumas and Laurence Chaperot (32),
researchers of the French National Blood Service (Etablissement
Français du Sang, EFS) and was deposited with the CNCM
(French National Collection of Microorganism Cultures) under
the number CNCMI-2938. The GEN2.2 cell line was grown on a
layer of mitomycin C (Sigma-Aldrich, St. Louis, MO, USA, Cat.
No. M4287)-treated murine MS5 feeder cells (ACC 441, Leibniz
Institute DSMZ-German Collection of Microorganisms and
Cell Cultures, Braunschweig, Germany) in RPMI 1640 medium
(Sigma-Aldrich, Cat. No. R8758) supplemented with 10% heat-
inactivated FBS (Life Technologies Corporation, Carlsbad, CA,
USA, Cat. No. 10270-106), 100 U/ml penicillin, 100µg/ml
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streptomycin (both from Biosera, Nuaille, France, Cat. No. XC-
A4122/100) and 5% non-essential amino acids (Life Technologies
Corporation, Cat. No. 11140050). For experiments, the GEN2.2
cells were removed from the feeder layer, subjected to small
interfering RNA (siRNA) transfection then seeded on 24-well
plates at a concentration of 5 × 105 cells/500 µl in RPMI 1640
medium (Sigma-Aldrich, Cat. No. R8758). Cells were grown and
incubated at 37◦C in 5% CO2 humidified atmosphere.
For virus propagation African green monkey kidney
epithelial Vero cell line (ATCC-CCL-81; The American
Type Culture Collection [ATCC], Manassas, VA, USA) was
used. Vero cells were grown in Dulbecco’s modified Eagle’s
minimal essential medium (DMEM; Sigma-Aldrich, Cat. No.
D6546) supplemented with 10% heat-inactivated FBS (Life
Technologies Corporation, Cat. No. 10270-106), 100 U/ml
penicillin, 100µg/ml streptomycin (both from Biosera, Cat. No.
XC-A4122/100) at 37◦C in a 5% CO2 humidified atmosphere.
Primary Cell Isolation and Culture
Human heparinized leukocyte-enriched buffy coats were
obtained from healthy blood donors drawn at the Regional
Blood Center of Hungarian National Blood Transfusion Service
(Debrecen, Hungary) in accordance with the written approval of
the Director of the National Blood Transfusion Service and the
Regional and Institutional Ethics Committee of the University of
Debrecen, Faculty of Medicine (Debrecen, Hungary).
Peripheral blood mononuclear cells (PBMC) were separated
from buffy coats by Ficoll-Paque Plus (GE Healthcare, Little
Chalfont, Buckinghamshire, UK, Cat. No. 17-1440-03) gradient
centrifugation.
Monocytes were purified from PBMCs by positive selection
using magnetic cell separation with anti-CD14-conjugated
microbeads (Miltenyi Biotech, Bergish Gladbach, Germany,
Cat. No. 130-050-201). Freshly isolated cells were subjected
to siRNA transfection then seeded in 24-well cell culture
plates at a density of 106 cells/ml in RPMI 1640 medium
(Sigma-Aldrich, Cat. No. R8758) supplemented with 10% heat-
inactivated FBS (Life Technologies Corporation, Cat. No. 10270-
106), 2mM L-glutamine (Biosera, Cat. No. XC-T1755/100), 100
U/ml penicillin, 100µg/ml streptomycin (both from Biosera,
Cat. No. XC-A4122/100), 80 ng/ml GM-CSF (Gentaur Molecular
Products, London, UK, Cat. No. 04-RHUGM-CSF-300 MCG)
and 50 ng/ml IL-4 (PeproTech, Brussels, Belgium, Cat. No. 200-
04) for 5 days.
Human pDCs were isolated from PBMCs by positive selection
using the human CD304 (BDCA-4/Neuropilin-1) MicroBead Kit
(Miltenyi Biotech, Cat. No. 130-090-532) then cultured in 48-well
cell culture plates at a density of 5 × 105 cells/500 µl in RPMI
1640 medium (Sigma-Aldrich, Cat. No. R8758) supplemented
with 10% heat-inactivated FBS (Life Technologies Corporation,
Cat. No. 10270-106), 2mM L-glutamine (Biosera, Cat. No.
XC-T1755/100), 100 U/ml penicillin, 100µg/ml streptomycin
(both from Biosera, Cat. No. XC-A4122/100), and 50 ng/ml
recombinant human IL-3 (Peprotech EC, Cat. No. AF-200-03).
Cells were incubated at 37◦C in 5% CO2 humidified
atmosphere.
Virus Propagation and Determination of
Viral Titer
Vesicular Stomatitis Virus (VSV; Indiana serotype), kindly
provided by Dr. Eszter Csoma (Department of Medical
Microbiology, University of Debrecen, Debrecen, Hungary), was
propagated in Vero cell line for 36 h at 37◦C. The supernatants
of infected cell cultures were harvested and the intact cells or cell
debris were removed by centrifugation at 1000 × g for 10min
at 4◦C. After filtration of the supernatants using 0.45µm sterile
syringe filter (Rephile, Bioscience Ltd., Shanghai, China, Cat. No.
RJF1345NH), the viral supernatants were transferred to Amicon
Ultra-15 100K centrifugal filter units (Millipore, Danvers, MA,
USA, Cat. No. UFC910024) and spinned at 4000 × g for 20min
at 4◦C. The concentrated virus was stored in aliquots at −80◦C
and used as the infecting stock of the virus.
Plaque assay was performed to determine the viral titer of the
virus stocks. Vero cells were seeded in 12-well tissue culture plates
and the confluent monolayer of the cells were inoculated with 10-
fold serial dilutions of the VSV stock for 1 h at 37◦C then overlaid
with 0.3% agarose (Sigma-Aldrich, Cat. No. A9539) in DMEM
(Sigma-Aldrich, Cat. No. D6546) supplemented with 2% heat-
inactivated FBS (Life Technologies Corporation, Cat. No. 10270-
106), 100 U/ml penicillin and 100µg/ml streptomycin (both
from Biosera, Cat. No. XC-A4122/100). After 2 days of culturing
at 37◦C the cells were fixed by 4% formaldehyde (Sigma-Aldrich,
Cat. No. F8775) for 1 h at room temperature then the agarose
layer was removed. To visualize the plaque formation 0.2% crystal
violet (Sigma-Aldrich, Cat. No. 46364) solution was added to
the wells for 5min. The plates were washed and dried, and the
number of plaque-forming units per milliliter was calculated.
For the VSV infection of human DCs, virus stocks were
diluted to the indicated multiplicity of infection (MOI) and were
added to cells for 18 or 24 h.
SiRNA-Mediated Gene Silencing
GEN2.2. cells or freshly isolated monocytes were left untreated
(ctrl), transfected with no siRNA (mock), NLRX1- (Assay ID:
s36063, Life Technologies, Cat. No. 4392420) and NLRC5
(Assay ID: s38591, Life Technologies, Cat. No. 4392420)-specific
Silencer Select Validated siRNAs and Silencer Select Negative
Control siRNA (scr; Life Technologies, Cat. No. 4390844) in
Opti-MEMmedium (Life Technologies, Cat. No. 11058021) in 4-
mm cuvettes (Bio-Rad Laboratories GmbH, Munich, Germany,
Cat. No. 1652088) using GenePulser Xcell instrument (Bio-
Rad). Following transfection the cells were seeded as described
previously.
Cell Stimulation
To induce RIG-I expression GEN2.2 cells were incubated
with 0.25µM CpG-A (ODN 2216; Hycult Biotech, Uden,
The Netherlands, Cat. No. HC4037) for 16 h. Thereafter
the cells were washed, re-seeded in 24-well plates in fresh,
complete RPMI 1640 medium and stimulated with 5′ppp-dsRNA
(InvivoGen, San Diego, CA, USA, Cat. No. tlrl-3prna-100),
a specific agonist of RIG-I or polyI:C-HMW (HMW: high
molecular weight; InvivoGen, Cat. No. tlrl-pic), a RIG-I/MDA5
agonist, both complexed with the transfection reagent LyoVecTM
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(InvivoGen, Cat. No. lyec-1), according to the manufacturer’s
recommendations. To induce RIG-I in primary pDCs, cells
were treated with 2.5µM CpG-A for 16 h prior to western blot
analysis. In separate experiments, GEN2.2 cells were exposed
to 1 or 2µM of CpG-B (ODN 2006; Hycult Biotech, Cat. No.
HC4039), and 1 or 2µg/ml of Imiquimod (InvivoGen, Cat.
No. tlrl-imqs) or PAM3CSK4 (InvivoGen, Cat. No. tlrl-pms) for
24 h. For moDCs, half of the medium was removed, replaced by
fresh medium then stimulation with 5′ppp-dsRNA/LyoVecTM or
polyI:C-HMW/LyoVecTM complex was performed as described
for GEN2.2 cells. For live virus infection untreated and CpG-A
pre-treated GEN2.2 cells and moDCs were infected with VSV at
a MOI of 1 and 10, respectively for 18 or 24 h.
Flow Cytometry
Phenotypical analysis of moDCs was performed by flow
cytometry using anti-CD209-FITC (Cat. No. 33013, Clone:
9E9A8), anti-CD40-FITC (Cat. No. 334306, Clone: 5C3), anti-
CD80-FITC (Cat. No. 305206, Clone: 2D10), anti-HLA-DR-
FITC (Cat. No. 327006, Clone: LN3), anti-CD14-PE (Cat. No.
367104, Clone: 63D3), anti-CD11c-PE (Cat. No. 301606, Clone:
3.9), anti-CD83-PE-Cy5 (Cat. No. 305310, Clone: HB15e), anti-
CD1a-APC (Cat. No. 300110, Clone: HI149), anti-CD1c-APC
(Cat. No. 331524, Clone: L161) and their isotype-matched
control antibodies (all from BioLegend, San Diego, CA, USA).
The viability of electroporated moDCs was also assessed by
flow cytometry using 7-aminoactinomycin-D (7-AAD; 10µg/ml;
Sigma-Aldrich, Cat. No. A9400) staining.
Fluorescence intensities were measured with FACSCalibur
cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and data
were analyzed with FlowJo software (Tree Star, Ashland, OR,
USA). Throughout data acquisition, 10,000 events were acquired
from each sample containing 100,000 stained cells. Cells were
gated on forward vs. side scatter to exclude cell debris. Isotype
controls were used to set gates for positive staining of CD14,
CD209, CD1a, CD1c, and CD11c. For 7-AAD staining the
unstained cells were used as negative control and the percentages
of 7-AAD negative live cells were determined by excluding
the 7-AAD positive necrotic cell population. Delta median
fluorescence intensity values (MFI) of CD40, CD80, CD83, and
HLA-DR were obtained by subtracting the MFI values of the
isotype control samples from the MFI of the positively stained
samples.
Quantitative Real Time PCR
Total RNA was isolated from 5 × 105 cells using Tri reagent
(Molecular Research Center, Inc., Cincinnati, OH, USA, Cat.
No. TR118). Total RNA was treated with DNase I (Thermo
Fisher Scientific, Waltham, MA, USA, Cat. No. AM2222) to
exclude amplification of genomic DNA then reverse transcribed
into cDNA using the High Capacity cDNA RT Kit of Applied
Biosystems (Carlsbad, CA, USA, Cat. No. 4368813). Gene
expression assays were purchased from Thermo Fisher Scientific
for NLRC5 (Assay ID: Hs01072148_m1, Cat. No. 4331182),
NLRX1 (Assay ID: Hs00226360_m1, Cat. No. 4331182), IFNB
(Assay ID: Hs01077958_s1, Cat. No. 4331182) and Integrated
DNA Technologies (Coralville, IA, USA) for IFNA1 (Assay
ID: Hs.PT.49a.3184790.g) and PPIA (cyclophilin A; Assay ID:
Hs.PT.58v.38887593.g). Quantitative PCR was performed using
the ABI StepOne Real-Time PCR System (Applied Biosystems)
and cycle threshold values were determined using the StepOne
v2.1 Software (Applied Biosystems). The relative amount of
mRNA (2−1CT) was obtained by normalizing to the PPIA
housekeeping gene in each experiment.
Western Blotting
Protein extraction was performed by lysing the cells in
Laemmli sample buffer and separated by SDS-PAGE using
7.5% polyacrylamide gels and electrotransferred to nitrocellulose
membranes (Bio-Rad, Cat. No. 162-0115). Non-specific binding
sites were blocked with 5% non-fat dry milk diluted in TBS
Tween buffer (50mM Tris, 0.5M NaCl, 0.05% Tween-20, pH
7.4). The following antibodies were used for protein detection:
anti-RIG-I (Cell Signaling, Danvers, MA, USA, Cat. No. 3743),
anti-MDA5 (Cell Signaling, Cat. No. 5321), anti-TBK1 (Cell
Signaling, Cat. No. 3504), anti-MAVS (Cell Signaling, Cat. No.
3993), anti-NLRC5 (clone 3H8, Millipore, Cat. No. MABF260),
anti-NLRX1 (Proteintech Group, Manchester, UK, Cat. No.
17215-1-AP), anti-IκBα (Cell Signaling, Cat. No. 4812), and
anti-β-actin (Santa Cruz Biotechnology, Cat. No. sc-47778). The
bound antibodies were labeled with anti-mouse (Bio-Rad, Cat.
No. 1721011), anti-rat (Bio-Rad, Cat. No. 5204-2504) or anti-
rabbit (GE Healthcare, Cat. No. NA934) horseradish peroxidase-
conjugated secondary antibodies and were visualized by the ECL
system using SuperSignal West Pico or Femto chemiluminescent
substrates (Thermo Scientific, Rockford, IL, USA, Cat. No. 34580
and 34095) and X-ray film exposure. Densitometric analysis of
immunoreactive bands was performed using Image Studio Lite
Software version 5.2 (LI-COR Biosciences, Lincoln, Nebraska
USA).
ELISA
Cell culture supernatants were collected at the indicated time
points and the TNF (Cat. No. 555212), IL-6 (Cat. No. 555220)
and IL-8 (Cat. No. 555244) levels were determined by the
BD OptEIA human ELISA kits (all from BD Biosciences, San
Diego, CA, USA). IFN-α and IFN-β levels were measured
by the VeriKineTM Human Interferon Alpha (Cat. No. RD-
41100-1) and Interferon Beta (Cat. No. RD-41410-1) ELISA
kits, respectively (PBL Interferon Sources, Piscataway, NJ,
USA). Assays were performed according to the manufacturer’s
instructions. Absorbance measurements were carried out by a
Synergy HT microplate reader (Bio-Tek Instruments, Winooski,
VT, USA) at 450 nm.
Statistical Analysis
Data are expressed as the Mean ± SD and analyzed by
Student’s unpaired t-test or ANOVA, followed by Bonferroni
post hoc analysis for least-significant differences. Data analysis
was performed with GraphPad Prism v.6. Software (GraphPad
Software Inc., La Jolla, CA, USA). All experiments were repeated
at least three times. Differences were considered to be statistically
significant at P < 0.05.
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RESULTS
The Expression of NLRC5 and RLRs but
Not of NLRX1 Is Upregulated by CpG-A
Treatment in the Human GEN2.2 pDC Cell
Line and in Primary Human pDCs
Human pDCs constitute a very rare cell population in peripheral
blood. Therefore, we performed most of our experiments with
the human pDC cell line called GEN2.2, which displays similar
phenotypic and functional properties to human primary pDCs
(33, 34). First, we sought to investigate the expression of NLRC5
and NLRX1 in resting and CpG-A stimulated pDCs. To this end,
GEN2.2 cells were stimulated with increasing concentrations of
the TLR9 ligand, CpG-A (0.25, 0.5, 1µM) in a time-dependent
manner. Our results show that NLRC5 is not expressed in resting
cells but appears both at the mRNA (Figure 1A) and protein
level (Figures 1B,C) upon exposure to all applied doses of CpG-
A showing a significant upregulation as early as 16 h. In contrast,
NLRX1 is constitutively expressed and is not affected by CpG-A
stimulation (Figures 1A-C).
In this set of experiments, we also tested the expression of
RLRs and downstream signaling molecules (Figures 1D,E). Both
RIG-I and MDA5 show a strong upregulation at 16 h upon
treatment with even the smallest dose of CpG-A, which correlates
with our previous data (27). Interestingly, synthetic ssRNAs and
dsRNAs have been found to downregulate MAVS expression
(35). In line with this data, we also observed decreased protein
levels of MAVS upon CpG-A treatment of GEN2.2 cells, the
mechanism of which might be essential to avoid overwhelming
host inflammatory responses. On the other hand, TBK1, a
key regulator of IFN signaling, was not affected by CpG-A
stimulation. As we have previously described 0.25µM of CpG-
A is able to upregulate RIG-I expression in GEN2.2 cells in a way
that it does not induce IFN production, and therefore does not
result in cell exhaustion (27). Since RIG-I, MDA5 and NLRC5
are greatly upregulated upon treatment with 0.25µM of CpG-A
at 16 h, we decided to use these culture conditions in our further
experiments with the GEN2.2 cell line.
Similar results were obtained using freshly isolated primary
human pDCs; namely NLRX1 is constantly expressed whereas
NLRC5 is inducible upon CpG-A stimulation (Figures 2A,B).
Furthermore, RIG-I, MDA5, MAVS, and TBK1 were all strongly
upregulated following CpG-A treatment (Figures 2C,D). Thus,
our observations indicate that GEN2.2 cells provide a relevant cell
model for studying NLR and RLR interactions in human pDCs.
Silencing of NLRC5 or NLRX1 Does Not
Alter the Expression of RLR Signaling
Components in GEN2.2 Cells
pDC are best known for their ability to produce high levels
of type I IFNs as well as a broad array of pro-inflammatory
cytokines in response to many viruses (36). We were curious
whether NLRs are able to regulate RIG-I-mediated antiviral
responses of pDCs. Therefore we performed siRNA-mediated
gene silencing to deplete NLRC5 and NLRX1 in GEN2.2 cells.
At 24 h post transfection cells were stimulated with 0.25µM of
CpG-A followed by which the efficacy of gene silencing and the
expression of RLR signaling molecules were verified by western
blot analysis (Figure S1). Our data show that gene silencing by
siRNAs significantly reduced the level of the targeted proteins
both in resting and activated cells (>80%; Figures S1A–D).
We also assessed RIG-I, MDA5 and MAVS protein levels in
order to reveal if depletion of either NLRC5 or NLRX1 impacts
their expression. We found that siRNA transfection did not
alter the expression pattern of RLR signaling proteins; MAVS is
not affected whereas RIG-I and MDA5 are absent from resting
GEN2.2 cells but inducible upon CpG-A stimulation regardless
of NLRC5 or NLRX1 silencing (Figures S1E–H).
NLRC5 and NLRX1 Inhibit Type I IFN
Responses but Not the Production of
Pro-Inflammatory Cytokines in GEN2.2
Cells
Following successful transfection, resting or CpG-A pre-treated
cells were activated with the specific RIG-I ligand 5′ppp-
dsRNA. Interestingly, NLRC5 and NLRX1 depletion increased
the transcript levels of IFNA1 and IFNB (Figure 3A) and
elicited a stronger IFN-α and IFN-β production to 5′ppp-dsRNA
(Figure 3B). These data demonstrate that both NLRC5 and
NLRX1 play negative regulatory roles in the RIG-I-mediated IFN
responses of human pDCs.
In addition to IFNs, pDC are also able to rapidly produce pro-
inflammatory cytokines and chemokines upon viral infection
(36); therefore we analyzed the secretion of the pro-inflammatory
cytokines IL-6, TNF, and the chemokine IL-8 protein in the cell
culture supernatants by ELISA. As shown in Figure 3C, low levels
of the investigated proteins were produced constitutively and
could be only slightly increased by RIG-I stimulation in GEN2.2
cells. Interestingly, in contrast to type I IFNs, the secretion of
TNF, IL-6 and IL-8 was not affected by NLRC5 or NLRX1
silencing. To further confirm that NLRC5 and NLRX1 do not
influence the NF-κB signaling pathway we measured NF-κB
activity by investigating the degradation kinetics of its inhibitory
protein, IκBα (Figure 3D). Degradation of IκBα releases the p50
and p65 subunits of NF-κB, allowing their nuclear translocation
and subsequent activation of target genes. Interestingly, RIG-I
stimulation failed to induce IκBα degradation that correlated
with the weak pro-inflammatory cytokine production suggesting
that RIG-I preferentially induces the production of type I IFNs
over pro-inflammatory cytokines in a non-canonical way in
pDCs, in accordance with previous reports from animal in vivo
studies (37).
In separate experiments, following CpG-A pre-treatment, cells
were re-stimulated with polyinosinic:polycytidylic acid, (polyI:C)
instead of the specific RIG-I agonist 5′ppp-dsRNA (Figure 4).
PolyI:C is a ligand for both cytoplasmic RIG-I/MDA5 and
endosomal TLR3 as well. Whereas naked polyI:C is recognized
by TLR3, transfected polyI:C is sensed by RIG-I/MDA5 (20).
In our experiments we used polyI:C-HMW/LyoVec, a complex
between high molecular weight polyI:C and the transfection
reagent LyoVec, which signals only through RLRs. Although,
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FIGURE 1 | The expression of NLRC5, RIG-I and MDA5 but not that of NLRX1 is upregulated by CpG-A treatment in the human GEN2.2 pDC cell line. (A–E) GEN2.2
cells were treated with increasing concentration of CpG-A (0.25–1µM) in a time dependent manner. The expression of NLRC5 and NLRX1 was measured at the
(Continued)
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FIGURE 1 | mRNA level by Q-PCR (A) and at the protein level by western blotting (B,C). The changes in protein levels of RIG-I, MDA5, MAVS, and TBK1 were also
analyzed after CpG-A treatments by western blotting (D,E). Representative blots are shown in (B,D). Data are shown as mean ± SD from 4 to 6 independent
experiments in panels (A,C,E). Data were analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
1µM CpG-A vs control; +p < 0.05, ++p < 0.01, +++p < 0.001, ++++p < 0.0001 0.5µM CpG-A vs control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p
< 0.0001 0.25µM CpG-A vs control.
FIGURE 2 | The expression of NLRC5, RIG-I, and MDA5 is inducible in primary human pDCs after CpG-A treatments. (A–D) Freshly isolated primary human pDCs
were stimulated with 2.5µM CpG-A for 16 h, thereafter the protein levels of NLRC5, NLRX1, RIG-I, MDA5, MAVS, and TBK1 were detected by western blotting.
Representative blots are shown in (A,C). Data are shown as mean ± SD from 3 to 4 experiments in panels (B,D). (B,D) Statistical comparisons were performed using
Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001.
LyoVec-conjugated polyI:C-HMW is an agonist both for RIG-
I and MDA5, studies have reported that it is preferentially
recognized by MDA5 (14, 38). We obtained very similar results
when polyI:C/LyoVec was used as a stimulant. NLRC5 and
NLRX1 depletion increased the polyI:C-mediated secretion of
type I IFNs (Figure 4A) but did not affect the production
of pro-inflammatory cytokines (Figure 4B) and NF-κB activity
(Figure 4C).
To further test the assumption that NLRC5 and NLRX1 does
not regulate the pro-inflammatory cytokine production in pDCs
we stimulated GEN2.2 cells with well-known stimulators of the
NF-κB signaling pathway including the TLR9 ligand CpG-B,
the TLR7 ligand imiquimod and the TLR1/2 receptor agonist
PAM3CSK4 (Figure S2A). The kinetics of IκBα degradation
revealed that CpG-B and imiquimod are strong inducers of
the NF-κB signaling route; therefore, we used these agonists to
induce a pro-inflammatory signal following depletion of NLRC5
and NLRX1. Our results demonstrate that neither NLRC5 nor
NLRX1 silencing has any effect on the TNF, IL-6 and IL-8
cytokine production upon CpG-B or imiquimod stimulation
(Figure S2B). These results confirm our observation that the
NF-κB signaling route is indeed not affected by NLRC5 and
NLRX1.
Collectively, our results indicate that NLRC5 and NLRX1
play a critical regulatory role in the RLR-mediated type I IFN
responses while not affecting NF-κB activity, and thus the pro-
inflammatory cytokine production of human pDCs.
Immature moDCs Constantly Express
NLRC5 and NLRX1, the Silencing of Which
Does Not Affect Their Differentiation and
the Expression of RLR Signaling
Components
Various DC subtypes show distinct inflammatory cytokine
profiles under steady-state and inflammatory conditions (39).
In order to investigate how NLRX1 and NLRC5 affect the
RIG-I mediated immune responses of other DC subsets, we
repeated our experiments with moDCs. Under inflammatory
conditions, monocytes can differentiate into moDCs, which
in response to microbial stimuli are able to produce large
amounts of pro-inflammatory and/or antiviral cytokines thus
contribute to the shaping of innate and adaptive immune
responses (40–42). Therefore, moDCs generated from CD14+
blood monocytes in the presence of GM-CSF and IL-
4 in vitro serve as an excellent model for studying DC
functionality.
First, we analyzed the expression profile of NLRC5,
NLRX1, and also RLR signaling molecules during moDC
differentiation as it is poorly characterized so far in human
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FIGURE 3 | The specific RIG-I agonist-induced type I IFN production is upregulated by NLRC5 or NLRX1 silencing while the NF-κB signaling pathway is not affected
in GEN2.2 cells. (A–D) Cells were transfected with siRNAs specific for NLRC5, NLRX1 or scrambled (scr) siRNAs for 24 h then pre-treated with 0.25µM CpG-A
(pre-CpG-A) for 16 h to induce the cytosolic expression of RLRs. Following thorough washing steps cells were stimulated with the specific RIG-I agonist 5′ppp-dsRNA
(RIGL, 1µg/ml). The IFNA1 and IFNB mRNA expression levels were assessed by real-time PCR after 3 h (A) and IFN-α, IFN-β (B), TNF, IL-6, and IL-8 (C) protein levels
were measured by ELISA after 6 (B) or 24 h (C). (D) Kinetics of IκBα degradation was determined by western blotting. (D) A representative blot is shown. (A–C) Data
are represented as means ± SD of 3-5 individual experiments and analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 vs. pre-CpG-A-treated samples; #p < 0.05, ####p < 0.0001, n.d., not determined.
cells (Figure 5). We found that NLRC5, NLRX1 are either
not detectable or only weakly expressed in freshly isolated
monocytes but are gradually upregulated during moDC
differentiation (Figures 5A,B). Similarly, RIG-I, MDA5 and
their downstream signaling components including MAVS and
TBK1 are all upregulated during the DC differentiation process
(Figures 5C,D).
In the next step, we performed RNA interference on
freshly isolated monocytes using a method we previously
applied successfully to silence target genes in moDCs
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FIGURE 4 | The RIG-I/MDA5 agonist-induced type I IFN production is upregulated by NLRC5 or NLRX1 silencing while the NF-κB signaling pathway is not affected in
GEN2.2 cells. (A–C) Cells were transfected with siRNAs specific for NLRC5, NLRX1 or scrambled (scr) siRNAs for 24 h then pre-treated with 0.25µM CpG-A
(pre-CpG-A) for 16 h to induce the cytosolic expression of RLRs. Following thorough washing steps cells were stimulated with the RIG-I/MDA5 agonist polyI:C (1
µg/ml). The protein levels of IFN-α, IFN-β (A), TNF, IL-6, and IL-8 (B) were measured by ELISA after 6 (A) or 24 h (B). (C) Kinetics of IκBα degradation was determined
by western blotting. (C) A representative blot is shown. Data are represented as means ± SD of 4 individual experiments and analyzed using one-way ANOVA
followed by Bonferroni’s post-hoc test. **p < 0.01, ***p < 0.0001, ****p < 0.0001 vs. pre-CpG-A-treated samples; ##p < 0.01, n.d., not determined.
(43). Monocytes were transfected with siRNAs specific for
NLRC5 and NLRX1, scrambled control siRNA as described in
“Materials and Methods” then the efficiency of gene silencing
was evaluated by western blot analysis on day 5 of moDC
differentiation (Figures S3A,B). Our data demonstrate a
successful downregulation of the target genes that does not affect
the expression of RIG-I, MDA5, or MAVS in immature moDCs
(Figures S3C,D).
To confirm that siRNA silencing does not interfere with
moDC differentiation we measured the expression of the
monocyte-specific marker, CD14, and DC-specific ICAM-3-
grabbing nonintegrin (CD209/DC-SIGN; Figure 6). Our results
show that the CD209/CD14 ratio increased at a comparable
level in cells transfected with siRNAs as compared with
untreated cells on day 5 of moDC differentiation, indicating
that inhibition of NLRC5 or NLRX1 does not influence the
differentiation processes of moDCs (Figure 6B). A profound
day-to-day analysis of CD209/CD14 ratio further confirmed that
neither NLRC5 norNLRX1 silencing influence the differentiation
process of monocytes into DCs (Figure S4). To further identify
the phenotype of differentiated moDC we also measured the
expression of surface markers characteristic of DCs including
CD1a, CD1c, and CD11c (Figure 6C). Our results demonstrate
that all DC specific markers are present in a high percentage
(CD1a: >71 %, CD1c: >98%, CD11c: 100%) on the surface of
immature moDCs regardless of NLRC5 and NLRX1 silencing.
We also assessed cell viability by using 7-AAD single staining
and found that it is not affected by siRNA transfection
(Figure 6C). To test whether NLRC5 and NLRX1 silencing
induce unintended maturation of moDCs, we also screened
5-day moDCs for co-stimulatory molecules and maturation
markers including CD40, CD80, CD83 and the MHC class
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FIGURE 5 | Human immature moDCs constantly express NLRC5, NLRX1, RIG-I and MDA5. (A–D) Freshly isolated monocytes were seeded in 24-well plates and
differentiated as described in the “Materials and Methods.” The protein levels of NLRC5, NLRX1, RIG-I, MDA5, MAVS, and TBK1 were measured by western blot.
(A,C) Representative blots are shown. (B,D) Graphs represent the kinetics of protein expressions during moDC differentiation. Data are represented as mean ± SD of
3–5 individual experiments and were analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01 vs. day 0.
II molecule HLA-DR (Figure S5). Our results indicate that
compared to the untreated or scrambled siRNA-transfected cells,
silencing with siRNAs specific for NLRC5 and NLRX1 did not
affect the expression of maturation markers, suggesting that
the cells remained in their immature state regardless of NLR
depletion.
RLR-Mediated Antiviral and
Pro-Inflammatory Responses Are Affected
by NLRX1 but Not by NLRC5 in moDCs
Following transfection, resting moDCs were stimulated with
the RIG-I specific ligand 5′ppp-dsRNA on day 5 and the
antiviral (Figures 7A,B) and pro-inflammatory cytokine profile
(Figure 7C) were analyzed. First we measured the expression
of IFN-α and IFNβ, the major type I IFNs produced by
moDCs. Interestingly, the RIG-I-mediated type I IFN expression
is not affected by NLRC5 silencing (Figures 7A,B), whereas it
is upregulated by NLRX1 silencing both at the mRNA and
protein levels (Figures 7A,B). TNF, IL-6 and IL-8 are secreted
at relatively low levels in immature moDCs but a significant
increase could be elicited by RIG-I stimulation (Figure 7C).
Similarly to GEN2.2 cells, the production of TNF, IL-6, and
IL-8 is not influenced by NLRC5 silencing in moDCs. On the
contrary, secretion of these cytokines is significantly increased
in cells silenced with NLRX1 siRNAs as compared to the
scrambled siRNA-transfected cells. The increased production
of the pro-inflammatory cytokines suggests elevated NF-κB
activity. Measuring the protein levels of IκBα, we have indeed
observed degradation at 60min of stimulation with 5′ppp-
dsRNA (Figures 7D,E).
Similarly to GEN2.2 cells we also stimulated moDCs
with polyI:C-HMW/LyoVec that induced the production of
type I IFNs and pro-inflammatory cytokines in a manner
comparable to 5′ppp-dsRNA (Figure 8). NLRX1 silencing
upregulated whereas NLRC5 depletion did not affect the type
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FIGURE 6 | The silencing of NLRC5 or NLRX1 does not influence the differentiation process of human immature moDCs. (A–C) Freshly isolated monocytes were
transfected with siRNAs specific for NLRC5, NLRX1, or scrambled (scr) siRNAs at day 0 and differentiated into immature moDCs. On day 5 of differentiation the
(Continued)
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FIGURE 6 | phenotypic analysis of the cells were perfomed by flow cytometry. Cells were gated on forward vs. side scatter to exclude debris (A) and the expression
levels of CD14 and CD209 (B) as well as CD1a, CD1c, and CD11c cell surface proteins and cell viability (C) were analyzed. (A–C) Representative dot blots are shown
from 3 individual experiments. (B, C) Isotype controls antibodies were used to set gates for positive events and numbers indicate the percentage of positive cells. In
case of 7AAD staining the numbers show the ratio of 7-AAD negative live cells.
FIGURE 7 | NLRX1 but not NLRC5 affects the specific RIG-I agonist-induced type I IFN and pro-inflammatory responses in human moDCs. (A–E) moDCs transfected
with the indicated siRNAs were stimulated with the RIG-I ligand 5′ppp-dsRNA (RIGL, 1µg/ml). The mRNA expression levels of IFNA1 and IFNB were assessed by
real-time PCR after 12 h (A) and IFN-α, IFN-β (B), TNF, IL-6, and IL-8 (C) protein levels were measured by ELISA after 24 h. (D,E) Kinetics of IκBα degradation was
determined by western blotting. (D) A representative blot is shown. (E) Bar graphs show the relative density of IκBα measured at 60min of stimulation. (A-C, E) Data
are shown as mean ± SD from 4 independent experiments and analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01,
***p < 0.01 ****p < 0.0001 vs. untreated; #p < 0.05, ###p < 0.001, ####p < 0.0001, n.d., not determined.
I IFN and pro-inflammatory cytokine production of moDCs
(Figures 8A,B). Furthermore, polyI:C-HMW/LyoVec induced
IκBα degradation at a similar rate as 5′ppp-dsRNA at 60min of
stimulation (Figures 8C,D).
Taken together, our results indicate that NLRX1 negatively
regulates both interferon and pro-inflammatory responses
initiated by RLRs, whereas NLRC5 does not seem to play any
regulatory role in these processes in moDCs.
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FIGURE 8 | NLRX1 but not NLRC5 controls the RIG-I/MDA5 agonist-induced type I IFN and pro-inflammatory responses in human moDCs. (A–D) moDCs transfected
with the indicated siRNAs were stimulated with the RIG-I/MDA5 ligand polyI:C (1µg/ml). The protein levels of IFN-α, IFN-β (A), TNF, IL-6, and IL-8 (B) were detected
by ELISA after 24 h. (C,D) Kinetics of IκBα degradation was determined by western blotting. (C) A representative blot is shown. (D) Bar graphs show the relative
density of IκBα measured at 60min of stimulation. (A,B,D) Data are shown as mean ± SD from 4 independent experiments and analyzed using one-way ANOVA
followed by Bonferroni’s post-hoc test. **p< 0.01, ***p< 0.01 ****p < 0.0001 vs. untreated; #p < 0.05, ##p < 0.01, ####p < 0.0001, n.d., not determined.
NLRC5 and NLRX1 Mediate Antiviral and
Pro-Inflammatory Responses to Live Virus
Infection of Human DCs
To strengthen our observations we also carried out experiments
with live virus both in GEN2.2 cells and moDCs. Following
transfection, CpG-A pre-treated cells were activated with VSV
at a MOI of 1 or 10 for 18 h. Compared to the synthetic ligands
5′ppp-dsRNA and polyI:C, VSV-induced type I IFN production
was increased both by NLRC5 and NLRX1 silencing (Figure 9A),
whereas the pro-inflammatory cytokine production was not
affected (Figure 9B).
We also wanted to investigate whether VSV is able to
upregulate the expression of RLRs similarly to the CpG-
A treatment. Our results indicate that RIG-I and MDA5
are strongly induced upon VSV infection (Figure 9C). These
observations prompted us to analyze the VSV-induced cytokine
responses of NLRC5- and NLRX1-depleted GEN2.2 cells that
were not pre-treated with CpG-A. We found that NLRC5 and
NLRX1 silencing resulted in similar cytokine profile of VSV-
infected GEN2.2 cells independently of CpG-A pre-treatment
(Figures 9D,E).
Repeating our experiments with moDCs we found that the
expression of RIG-I and MDA5 is not affected by infection
with VSV at a MOI of 1 whereas strongly decreased at a MOI
of 10 (Figure 10A). Compared to the synthetic ligands 5′ppp-
dsRNA and polyI:C, VSV at a MOI of 1 induced type I IFN
and pro-inflammatory cytokine production that was increased
upon NLRX1 depletion but not affected by NLRC5 silencing
(Figures 10B,C). Interestingly, in contrast to GEN2.2 cells,
moDCs were much more sensitive to virus infection as VSV at a
MOI of 10 failed to elicit increased cytokine production, which
might be explained by the decreased expression of RIG-I and
MDA5 caused by VSV infection.
All these data demonstrate that NLRX1 and NLRC5 can
control the type I IFN and pro-inflammatory responses to live
virus infection of human DCs as well.
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FIGURE 9 | Depletion of NLRC5 or NLRX1 enhances the type I IFN production of GEN2.2 cells but does not influence the NF-κB pathway activity in response to VSV
infection. (A–E) Cells were transfected with siRNAs specific for NLRC5, NLRX1 or scrambled (scr) siRNAs for 24 h. (A,B) After silencing cells were pre-treated with
(Continued)
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FIGURE 9 | 0.25µM CpG-A (pre-CpG-A) for 16 h to induce the cytosolic expression of RLRs. Following thorough washing steps cells were infected with VSV at the
indicated MOIs. The protein levels of IFN-α, IFN-β (A), TNF, IL-6, and IL-8 (B) were measured by ELISA after 18 h. (C–E) After silencing GEN2.2 cells were exposed to
VSV at the indicated MOIs without CpG-A pre-treatment and the protein levels of RIG-I and MDA5 were detected by western blot at 24 h (C). Concentrations of IFN-α,
IFN-β (D), TNF, IL-6, and IL-8 (E) were measured by ELISA from the supernatant of the VSV-infected cells. (C) A representative blot is shown. Data are represented as
means ± SD of 4 individual experiments and analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.0001, ****p <
0.0001 vs. untreated; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001, n.d., not determined.
FIGURE 10 | NLRX1 but not NLRC5 affects the type I IFN and pro-inflammatory responses in VSV-infected human moDCs. (A–C) moDCs transfected with the
indicated siRNAs were exposed to VSV at the indicated MOIs and after 18 h the protein levels of RIG-I and MDA5 (A) were analyzed by western blotting, and the
concentrations of secreted IFN-α, IFN-β (B), TNF, IL-6, and IL-8 (C) were determined by ELISA. (A) A representative blot is shown. (B,C) Data are shown as mean ±
SD from 4 independent experiments and analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.01 ****p < 0.0001
vs. untreated; ##p < 0.01, ###p < 0.001, n.d., not determined.
DISCUSSION
During the course of infections a fundamental role of the
host immune system is to induce a rapid and robust immune
response to eradicate invading pathogens and then resolve
inflammation to restore tissue homeostasis and to induce
regenerative processes. A broad range of PRRs are responsible
for initiating signaling cascades that mediate the innate immune
response following viral infections (1). RLRs recognize viral
nucleic acids in the cytosol and signal through MAVS to
initiate downstream effector molecules such as type I IFNs and
other pro-inflammatory cytokines that serve to mount a local
antiviral response (6, 10). Although activation of RLR signaling
is necessary to limit the spread of viruses, stringent regulation is
needed to prevent excessive immune response that may result in
tissue damage and further detrimental antiviral effects on the host
(44). RLR-mediated innate immune signaling has been found
to be regulated by several regulatory molecules that exert their
function both in the steady state and upon viral infection (45).
It has been recently recognized that tripartite motif containing
29 (TRIM29) plays a negative regulatory role in type I IFN
production in response to polyI:C or dsRNA virus infection
in bone marrow–derived DCs and macrophages as well as in
response to 5′ppp-RNA inmurine alveolar macrophages (46, 47).
Furthermore, several members of the NLR family have been
also proposed to serve as checkpoint of immune activation, with
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NLRC5 and NLRX1 directly interacting with the RIG-I mediated
antiviral signaling (4, 29).
NLRX1 was initially characterized as a negative regulator of
antiviral responses (48). Moore and colleagues described that
NLRX1 localizes to the mitochondrial outer membrane where
it interacts with MAVS and results in the attenuation of RLR
signaling pathways in human epithelial HEK293T cells (48).
Since then, several studies have examined the importance of
NLRX1 during antiviral signaling both in vitro and in vivo,
but have produced conflicting results and the role of NLRX1
remained controversial. Similarly to the initial report, Allen
et al. demonstrated that NLRX1−/− mice exhibit increased
expression of antiviral signaling molecules such as IFN-β and
IL-6 following exposure to viruses, which activate RIG-I (49).
In contrast, another group reported that NLRX1 deficiency
does not affect RLR/MAVS signaling (50). In a subsequent
study, normal antiviral and inflammatory responses have been
observed following Sendai virus infection of bone marrow-
derived macrophages and murine embryonic fibroblasts from
NLRX1-deficient mice (51). Furthermore, an independent study
reported that NLRX1-silenced HEK293T cells infected with
Sendai virus displayed normal type I IFN response (52). Here
we show that NLRX1 is constitutively expressed both in human
pDCs and moDCs and interferes with the RIG-I-mediated
type I IFN production in these cell types. So far one study
has proposed a role for NLRX1 in human DCs, showing
that NLRX1 promotes HIV-1 infection in multiple cell types
including human primary macrophages and DCs (53). We found
that NLRX1 silencing significantly increased pro-inflammatory
cytokine (TNF, IL-6) and chemokine (IL-8) secretion in moDCs
but not in pDCs following RLR stimulation. These findings were
further supported by the observation that IκBα is degraded only
in NLRX1-depleted moDCs upon stimulation with the RIG-I
ligand 5′ppp-dsRNA or the RIG-I/MDA5 agonist polyI:C. Thus,
our results indicate that NLRX1 predominantly acts as a negative
regulator of RLR/MAVS signaling in human DCs.
NLRC5 is primarily known as an MHC class I transactivator,
which following activation localizes to the nucleus and induces
the promoters of MHC class I genes (54). NLRC5 is widely
expressed in hematopoietic cells and can be greatly induced by
type I and II IFNs produced in response to pathogenic infections
(55). Consistent with these observations, we demonstrate that
NLRC5 is gradually upregulated in differentiating moDC and
upon TLR9 activation in pDCs.
Increasing evidence indicates that NLRC5 contributes to
innate and adaptive immune responses, though the published
studies present apparently conflicting results. In the context of
virus infection NLRC5 was initially reported to be a positive
regulator of type I IFN responses (56). The authors show that
siRNA-mediated silencing of NLRC5 impairs the upregulation
of IFN-α after human cytomegalovirus infection of human
foreskin fibroblasts (56). Similar results on the function of
NLRC5 were reported by another group demonstrating that
knockdown of endogenous NLRC5 impairs type I IFN responses
in THP1 cells and human primary dermal fibroblast in response
to Sendai virus and polyI:C (57). By contrast, another group
showed that NLRC5 negatively regulates the NF-κB and type
I IFN pathways by direct interaction with IκB kinase (IKK)
and RIG-I in multiple cell lines and primary cells (58). In
detail, following viral infection or stimulation by specific ligands,
the caspase recruitment domain (CARD) of RIG-I and MDA5
becomes accessible for NLRC5 which competes with MAVS
for binding, thus leading to dampened IRF3 activation (58).
In a subsequent study the same group generated NLRC5
knockout mice and found that NLRC5 deficiency increased
IL-6 and IFN-β production in mouse embryonic fibroblast,
peritoneal and bone marrow-derived macrophages but not in
bone marrow-derived DCs following vesicular stomatitis virus
infection or lipopolysaccharide stimulation (59). Interestingly, a
study by Kumar et al. suggests that NLRC5 is dispensable for
cytokine induction in bone marrow-derived macrophages and
DCs in response to a range of viral and bacterial infections
(60). The authors also published that NLRC5 directly binds to
TBK1 and suppresses TBK1-mediated IFN-β promoter activation
in HEK293T cells (60). Our data demonstrate that NLRC5
acts as a negative regulator of type I IFN production of
pDCs but not of moDCs. Investigating the role of NLRC5
in RLR-mediated pro-inflammatory signaling we could not
detect any differences between control and NLRC5-depleted
pDCs and moDCs. Altogether, our results suggest that NLRC5
modulates RLR-mediated type I IFN responses but not the
pro-inflammatory signaling of pDCs and seems to play no
role in the control of RIG-I signaling pathway dynamics in
moDCs.
Finally, to confirm our findings both pDC cell line and
moDCs were infected with live, replicating viruses. Since there
are not any virus strains that are exclusively recognized by RIG-I
or MDA5, we decided to use VSV, a single-stranded negative-
sense RNA virus in our experiments. VSV is preferentially
recognized by RLRs, but can also be detected by TLR7 (9,
61). The results obtained by virus infection were consistent to
those observed using the synthetic ligands 5′ppp-dsRNA and
polyI:C both in GEN2.2 cells and moDCs. Further, we tested
whether VSV is able to induce RLR expression in GEN2.2
cells and found that both RIG-I and MDA5 are significantly
upregulated after 24 h of infection. Previously, we published that
both endosomal TLR7 and TLR9 are able to upregulate RIG-
I expression in human pDCs (26); thus, we assume that the
initial recognition and triggering of RLR expression might be
mediated by TLR7. In contrast to pDCs, moDCs were more
sensitive to infection with VSV. At high viral dose, we observed
degradation of RIG-I and MDA5 proteins that consequently
lead to lower cytokine production. It is known that pDCs
possess faster and stronger IFN producing abilities compared
to other cell types including moDCs (62). Our results also
indicate that pDCs are better equipped with antiviral proteins
that exert a protective effect against the cytopathic effects of
VSV.
Recently several studies have tried to unfold the role
of regulatory NLRs in antiviral signaling pathways, however
yielded inconsistent findings. The discrepancies can be attributed
to several factors such as the different cell types/lines and
silencing/overexpression techniques used in each study that
might greatly influence the results. Several of the aforementioned
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studies applied luciferase reporter assays to measure the activity
of signal transduction pathways; however, a recent study has
indicated that this technique is not suitable to analyze the role
of NLRs due to the presence of leucine rich repeat domain that
induces nonspecific aggregation and degradation of luciferase
and leads to misinterpretation of experimental data (52). To
overcome these limitations, we used siRNA-based silencing
technique in our experiments and achieved substantial depletion
of NLRC5 and NLRX1 proteins. Our data obtained from
transfection experiments are in line with the reports of Allen
et al. and Cui et al. (49, 58) indicating that the RLR-mediated
antiviral responses are negatively regulated by NLRX1 and at
least partially by NLRC5. All these observations including ours
support the idea that NLRC5 andNLRX1 as regulatory NLRs play
a physiologically important role in the maintenance of immune
homeostasis, especially in the modulation of innate immune
responses.
Accumulating evidence suggest that aberrant IFN
production due to abnormal RLR activation is associated
with the development of autoimmune diseases (7). Therefore,
understanding the molecular mechanisms underlying the
negative regulation of innate immunity might contribute to the
development of effective therapies for inflammation-induced
autoimmune diseases. From another aspect, these regulatory
NLRs working as molecular breaks on antiviral signaling
might serve as potential therapeutic targets for enhancing host
responses to pathogenic infection.
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